Table 5.
Stability results.
| ARV | N CPL testing original sample | N† excluded CPL testing original sample | Median for original results | N CPL testing stability sample | N† excluded CPL testing stability sample | Median for stability results | Median, % recovery | Storage duration | Kruskal–Wallis test, p-value |
|---|---|---|---|---|---|---|---|---|---|
| DRV | 6 | 1 | 1547 | 8 | 1 | 1581 | 102% | 2.58 | 0.606 |
| DRV | 7 | 0 | 3955 | 9 | 0 | 3920 | 99% | 2.50 | 0.634 |
| FTC | 3 | 0 | 611 | 4 | 1 | 606 | 99% | 3.58 | 1.00 |
| FTC | 5 | 0 | 587 | 5 | 1 | 576 | 98% | 3.50 | 0.753 |
| FTC | 4 | 1 | 823 | 4 | 1 | 804 | 98% | 2.50 | 0.564 |
| FTC | 7 | 0 | 184 | 5 | 1 | 179 | 97% | 2.50 | 0.464 |
| NVP | 6 | 0 | 757 | 7 | 0 | 706 | 93% | 3.50 | 0.568 |
| NVP | 6 | 0 | 1636 | 7 | 0 | 1589 | 97% | 3.50 | 0.391 |
| NVP | 7 | 0 | 3140 | 5 | 0 | 2956 | 94% | 2.50 | 0.062 |
| RGV | 4 | 0 | 346 | 6 | 0 | 350 | 101% | 3.50 | 0.831 |
| RGV | 4 | 0 | 818 | 6 | 0 | 807 | 98% | 3.50 | 0.670 |
| RGV | 3 | 0 | 1745 | 6 | 0 | 1539 | 88% | 2.58 | 0.121 |
| RGV | 4 | 0 | 1004 | 6 | 0 | 989 | 98% | 2.50 | 0.831 |
| TFV | 3 | 0 | 221 | 4 | 0 | 203 | 92% | 3.58 | 1.00 |
| TFV | 4 | 0 | 126 | 6 | 0 | 113 | 90% | 3.50 | 0.286 |
| TFV | 5 | 0 | 148 | 4 | 0 | 146 | 99% | 2.58 | 0.327 |
| TFV | 6 | 0 | 129 | 6 | 0 | 120 | 93% | 2.50 | 0.229 |
†
Values excluded when Grubbs test identified as outlier or laboratory failed proficiency for the ARV Thinner line segregates ARV stability testing occurring in more than one round.
% recovery = 100% × (stability test value/final proficiency test target value in original testing round).
ARV: Antiretroviral; ATV: Atazanavir; CPL: Clinical pharmacology laboratory; DRV: Darunavir; EFV: Efaviren; FTC: Emtricitabine; LPV:Lopinavir; N: Number; NVP: Nevirapine; RGV: Raltegravir; RPD: Relative percentage difference; RTV: Ritonavir; TFV: Tenofovir.